Table 2.
Factors associated with telomere length (T/S ratio), robust regression analyses*
| Characteristic | Univariate model | Initial multivariate model | Final multivariate model |
|---|---|---|---|
| Regression | Regression | Regression | |
| coefficient (95%CI) p-value | coefficient (95%CI) p-value | coefficient (95%CI) p-value | |
| Age (year) | −0.0025(−0.0079, 0.0028) 0.36 |
||
| Male sex (%) | −0.0012(−0.0749, 0.0724) 0.97 |
||
| Cigarette smoking | −0.1222(−0.2130,−0.0314) 0.008 |
−0.0292(−0.1240,0.0656) 0.54 |
|
| Daily alcohol use | −0.1143(−0.1813,−0.0473) 0.0008 |
−0.1125(−0.1829,−0.0422) 0.002 |
−0.1109(−0.1778,−0.0441) 0.001 |
| Cocaine use | −0.1126(−0.2091,−0.0161) 0.02 |
−0.0607(−0.1320,0.0105) 0.09 |
−0.0781(−0.1454,−0.0108) 0.02 |
| Daily cocaine use | −0.0692(−0.1373,−0.0012) 0.046 |
||
| BMI (kg/m2) | 0.0018(−0.0093, 0.0129) 0.75 |
||
| Systolic BP (mm Hg) | −0.0019(−0.0039, 0.0001) 0.06 |
−0.0015(−0.0038,0.0008) 0.21 |
|
| Diastolic BP (mm Hg) | −0.0028(−0.0059, 0.0003) 0.08 |
0.0001(−0.0014,0.0017) 0.88 |
|
| hsCRP (mg/dL) | 0.0022(−0.0027,0.0071) 0.38 |
||
| Glucose (mg/dL) | −0.0006(−0.0023, 0.0010) 0.46 |
||
| Total cholesterol (mg/dL) | 0.0000(−0.0007, 0.0008) 0.93 |
||
| LDL-C (mg/dL) | 0.0000(−0.0008, 0.0009) 0.91 |
||
| HDL-C (mg/dL) | −0.0011(−0.0026, 0.0005) 0.18 |
||
| Triglycerides (mg/dL) | −0.0001(−0.0005, 0.0004) 0.72 |
||
| The 2013 risk (%) | −0.4600(−0.9312, 0.0111) 0.055 |
||
| Low 2013 risk | 0.0759(0.0085, 0.1433) 0.027 |
0.0585(−0.0168,0.1338) 0.13 |
0.0771(0.0116,0.1427) 0.02 |
| Years since HIV was diagnosed | 0.0044(−0.0029, 0.0117) 0.24 |
||
| CD4 nadir (cells/mm3) | −0.0003(−0.0008, 0.0002) 0.23 |
||
| Maximum HIV RNA (copies/mL, log10 scale) | −0.0228(−0.0894, 0.0438) 0.50 |
||
| Months of NRTI use | −0.0001(−0.0006, 0.0004) 0.80 |
||
| Months of NNRTI use | 0.0003(−0.0007, 0.0013) 0.60 |
||
| Months of PI use | −0.0002(−0.0006, 0.0003) 0.50 |
Abbreviations: BMI, body mass index (kg/m2); hsCRP, high-sensitivity C-reactive protein; BP, blood pressure; LDL-C, low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol; glucose, fasting glucose; the 2013 risk, cardiovascular risk defined by the 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk (Goff et al., 2014), low 2013 risk, the 2013 risk<0.075% (Goff et al., 2014), CD4 nadir, the lowest CD4 cell count recorded, maximum HIV RNA, the highest HIV viral load level recorded, ART, antiretroviral therapy, NRTI, nucleoside reverse transcriptase inhibitor, NNRTI, non-nucleoside reverse transcriptase inhibitor, PI, protease inhibitor.